Click here to view online. Add this email to your safelist.
Lynparza receives additional and broad approval in the US for ovarian cancer
17 August 2017
Lynparza’s new tablet formulation approved as maintenance treatment for women with platinum-sensitive recurrent ovarian cancer regardless of BRCA-mutation status. Lynparza tablets also indicated in BRCA-mutated ovarian cancer beyond the third-line setting. Newly-approved tablet formulation means improved patient convenience.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
